Pay in 4 interest-free payments of $7.41 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
correct technique and site rotation reduce their frequency
Developed by Eli Lilly as a triple-receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, retatrutide achieved a mean body weight reduction of -24.2% at its highest dose over 48 weeks surpassing both semaglutide and tirzepatide in their respective pivotal trials
In addition, GLP-1RAs could adjust the levels of the satiety signal in the arcuate nucleus in the hypothalamus, thereby increasing satiety and reducing caloric intake (179)
Since no human clinical trials exist, these numbers are based on animal research and years of community experience
The compounded preparation you receive from Trimi is made per your individual prescription by a licensed 503A pharmacy and is not itself FDA-approved as a drug
